- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Exo Debuts New Point-of-Care Ultrasound Modality
The Exo Iris reportedly combines advanced silicon technology with imaging, workflow software and artificial intelligence (AI) to facilitate multidisciplinary use of point-of-care ultrasound.
Emphasizing ease of use, enhanced imaging quality and artificial intelligence features, Exo has launched the Exo Iris point-of-care ultrasound modality.
In addition to acquiring images with a sweep of one’s wrist via patented SweepAI™ technology, the Exo Iris blends silicon technology with piezoelectric crystals to facilitate rapid delivery of image quality, according to Exo.
The company said other features of Exo Iris include the ability of the ultrasound platform to provide multi-organ scans, assess fine structures and offer guidance for IVs and line procedures.
Key AI features include assessment of bladder volume in seconds with Bladder AI and forthcoming real-time guidance and triage capabilities with Cardiac and Lung AI suites that are pending FDA 510(k) clearance, according to Exo.
“Exo Iris delivers an entirely new approach to the design of ultrasound; one that doesn’t look at ultrasound as a device-only purchase, but seamlessly brings together a complete solution that includes imaging, workflow, and real-time AI in one platform,” noted Arun Nagdev, M.D., the senior director of clinical education at Exo.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
